Free shipping on all orders over $ 500

CP-105,696

Cat. No. M8116

All AbMole products are for research use only, cannot be used for human consumption.

CP-105,696 Structure
Size Price Availability Quantity
5mg USD 160 In stock
10mg USD 255 In stock
25mg USD 505 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CP-105,696 is an orally active, potent and selective leukotriene B4 receptor (LTB4R) antagonist (IC50 against [3H]LTB4 = 5.6 nM for binding human neutrophils; IC50 = 9.7 nM & 30.3 nM, respectively using guinea pig spleen or mouse membranes) that targets LTB4R high- and low-affinity binding sites in a LTB4 non-competitive and competitive manner, respectively. CP-105,696 inhibits 5 nM LTB4-induced human neutrophils chemotaxis and CDllb upregualtion (IC50 = 5.2 nM and 430 nM, respectively) without inhibiting cyclooxygenase activity or affecting chemotaxis induced by C5a, PAF, IL-8. Oral administration is efficacious against intradermal LTB4 (100 ng/mouse), but not IL-1, injection-induced neutrophil accumulation in mice and guinea pigs (ED50 = 4.2 and 0.26 mgkg, respectively). CP-105,696 in vivo efficacy is also demonstrated in other animal models, including collagen-induced arthritis (CIA; 0.3-10 mg/kg in mice), allergic encephalomyelitis (ED50= 8.6 mg/kg; mice), and asthma (10-30 mg/kg; primate).

Chemical Information
Molecular Weight 428.52
Formula C28H28O4
CAS Number 158081-99-3
Form Solid
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Anne-Sophie Archambault, et al. 20-Hydroxy- and 20-carboxy-leukotriene (LT) B 4 downregulate LTB 4 -mediated responses of human neutrophils and eosinophils

[2] Barbara Maximino Rezende, et al. Inhibition of 5-lipoxygenase alleviates graft-versus-host disease

[3] T E Liston, et al. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration

[4] H J Showell, et al. Characterization of the pharmacological profile of the potent LTB4 antagonist CP-105,696 on murine LTB4 receptors in vitro

[5] C R Turner, et al. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma

Related Leukotriene Receptor Products
Pranlukast

Pranlukast is a selective cysteinyl leukotriene receptor antagonist.

Zafirlukast

Zafirlukast is a leukotriene receptor antagonist (LTRA) with IC50 of 0.6μM (IC50=7.0 µM for CYP2C9).

Cyclopentyl Chloroformate

Mandelic acid derivatives and their use as thrombin inhibitors.

LY255283

LY255283 is a competitive leukotriene B4 receptor antagonist, with an IC50 of about 100 nM.

CP-424174

CP-424174 is a cytokine release inhibitory compound (CRID) and also a reversible IL-1β inhibitor with an IC50 of 210 nM, which inhibits post-translational processing and secretion of IL-1β in human monocytes in the presence of LPS and ATP.

  Catalog
Abmole Inhibitor Catalog




Keywords: CP-105,696 supplier, Leukotriene Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.